{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T18:37:51Z","timestamp":1787769471180,"version":"build-2784847793"},"reference-count":18,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,8,21]],"date-time":"2025-08-21T00:00:00Z","timestamp":1755734400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,8,21]],"date-time":"2025-08-21T00:00:00Z","timestamp":1755734400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Radiat Oncol"],"DOI":"10.1186\/s13014-025-02691-y","type":"journal-article","created":{"date-parts":[[2025,8,21]],"date-time":"2025-08-21T05:27:38Z","timestamp":1755754058000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Use of PULSAR (personalized ultra-fractionated stereotactic adaptive radiotherapy) as consolidation with immune checkpoint inhibition in the treatment of pediatric metastatic melanoma"],"prefix":"10.1186","volume":"20","author":[{"given":"Kyra L.","family":"McCarty","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tanya","family":"Watt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tu D.","family":"Dan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert D.","family":"Timmerman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kiran A.","family":"Kumar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,8,21]]},"reference":[{"issue":"2","key":"2691_CR1","doi-asserted-by":"publisher","first-page":"186","DOI":"10.1200\/JCO.22.01763","volume":"10","author":"MB Atkins","year":"2023","unstructured":"Atkins MB, Lee SJ, Chmielowski B, et al. Combination Dabrafenib and Trametinib versus combination nivolumab and ipilimumab for patients with advanced BRAF-Mutant melanoma: the DREAMseq Trial-ECOG-ACRIN EA6134. J Clin Oncol Jan. 2023;10(2):186\u201397. https:\/\/doi.org\/10.1200\/JCO.22.01763.","journal-title":"J Clin Oncol Jan"},{"issue":"4","key":"2691_CR2","doi-asserted-by":"publisher","first-page":"582","DOI":"10.1093\/annonc\/mdz011","volume":"1","author":"O Hamid","year":"2019","unstructured":"Hamid O, Robert C, Daud A, et al. Five-year survival outcomes for patients with advanced melanoma treated with pembrolizumab in KEYNOTE-001. Ann Oncol Apr. 2019;1(4):582\u20138. https:\/\/doi.org\/10.1093\/annonc\/mdz011.","journal-title":"Ann Oncol Apr"},{"issue":"9","key":"2691_CR3","doi-asserted-by":"publisher","first-page":"1239","DOI":"10.1016\/S1470-2045(19)30388-2","volume":"20","author":"C Robert","year":"2019","unstructured":"Robert C, Ribas A, Schachter J, et al. Pembrolizumab versus ipilimumab in advanced melanoma (KEYNOTE-006): post-hoc 5-year results from an open-label, multicentre, randomised, controlled, phase 3 study. Lancet Oncol Sep. 2019;20(9):1239\u201351. https:\/\/doi.org\/10.1016\/S1470-2045(19)30388-2.","journal-title":"Lancet Oncol Sep"},{"issue":"24","key":"2691_CR4","doi-asserted-by":"publisher","first-page":"3998","DOI":"10.1200\/JCO.22.01599","volume":"20","author":"C Robert","year":"2023","unstructured":"Robert C, Carlino MS, McNeil C, et al. Seven-Year Follow-Up of the phase III KEYNOTE-006 study: pembrolizumab versus ipilimumab in advanced melanoma. J Clin Oncol Aug. 2023;20(24):3998\u20134003. https:\/\/doi.org\/10.1200\/JCO.22.01599.","journal-title":"J Clin Oncol Aug"},{"issue":"17","key":"2691_CR5","doi-asserted-by":"publisher","first-page":"4685","DOI":"10.1158\/1078-0432.CCR-21-0327","volume":"1","author":"L Marcus","year":"2021","unstructured":"Marcus L, Fashoyin-Aje LA, Donoghue M, et al. FDA approval summary: pembrolizumab for the treatment of tumor mutational Burden-High solid tumors. Clin Cancer Res Sep. 2021;1(17):4685\u20139. https:\/\/doi.org\/10.1158\/1078-0432.CCR-21-0327.","journal-title":"Clin Cancer Res Sep"},{"issue":"1","key":"2691_CR6","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1016\/S1470-2045(19)30671-0","volume":"21","author":"B Geoerger","year":"2020","unstructured":"Geoerger B, Kang HJ, Yalon-Oren M, et al. Pembrolizumab in paediatric patients with advanced melanoma or a PD-L1-positive, advanced, relapsed, or refractory solid tumour or lymphoma (KEYNOTE-051): interim analysis of an open-label, single-arm, phase 1\u20132 trial. Lancet Oncol Jan. 2020;21(1):121\u201333. https:\/\/doi.org\/10.1016\/S1470-2045(19)30671-0.","journal-title":"Lancet Oncol Jan"},{"issue":"3","key":"2691_CR7","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1016\/j.semradonc.2021.03.004","volume":"31","author":"Z Morris","year":"2021","unstructured":"Morris Z, Dohopolski M, Rahimi A, Timmerman R. Future directions in the use of SAbR for the treatment of oligometastatic cancers. Semin Radiat Oncol Jul. 2021;31(3):253\u201362. https:\/\/doi.org\/10.1016\/j.semradonc.2021.03.004.","journal-title":"Semin Radiat Oncol Jul"},{"key":"2691_CR8","doi-asserted-by":"publisher","first-page":"100605","DOI":"10.1016\/j.ctro.2023.100605","volume":"40","author":"S Tubin","year":"2023","unstructured":"Tubin S, Vozenin MC, Prezado Y, et al. Novel unconventional radiotherapy techniques: current status and future perspectives - Report from the 2nd international radiation oncology online seminar. Clin Transl Radiat Oncol May. 2023;40:100605. https:\/\/doi.org\/10.1016\/j.ctro.2023.100605.","journal-title":"Clin Transl Radiat Oncol May"},{"key":"2691_CR9","doi-asserted-by":"publisher","unstructured":"Dubben HH, Krull A, Beck-Bornholdt HP. May. Split-course radiotherapy: where do we stand? Strahlenther Onkol. 2001;177(5):227\u201339. https:\/\/doi.org\/10.1007\/pl00002402","DOI":"10.1007\/pl00002402"},{"key":"2691_CR10","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1016\/j.radonc.2020.04.039","volume":"149","author":"Y Alayed","year":"2020","unstructured":"Alayed Y, Quon H, Ong A, et al. Accelerating prostate stereotactic ablative body radiotherapy: efficacy and toxicity of a randomized phase II study of 11 versus 29 days overall treatment time (PATRIOT). Radiother Oncol Aug. 2020;149:8\u201313. https:\/\/doi.org\/10.1016\/j.radonc.2020.04.039.","journal-title":"Radiother Oncol Aug"},{"issue":"1","key":"2691_CR11","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1016\/j.ijrobp.2019.12.033","volume":"1","author":"SI Gutiontov","year":"2020","unstructured":"Gutiontov SI, Pitroda SP, Chmura SJ, Arina A, Weichselbaum RR. Cytoreduction and the optimization of immune checkpoint Inhibition with radiation therapy. Int J Radiat Oncol Biol Phys Sep. 2020;1(1):17\u201326. https:\/\/doi.org\/10.1016\/j.ijrobp.2019.12.033.","journal-title":"Int J Radiat Oncol Biol Phys Sep"},{"issue":"1","key":"2691_CR12","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1186\/s40425-018-0361-7","volume":"4","author":"J Gong","year":"2018","unstructured":"Gong J, Le TQ, Massarelli E, Hendifar AE, Tuli R. Radiation therapy and PD-1\/PD-L1 blockade: the clinical development of an evolving anticancer combination. J Immunother Cancer Jun. 2018;4(1):46. https:\/\/doi.org\/10.1186\/s40425-018-0361-7.","journal-title":"J Immunother Cancer Jun"},{"issue":"5","key":"2691_CR13","doi-asserted-by":"publisher","first-page":"1306","DOI":"10.1016\/j.ijrobp.2021.03.047","volume":"1","author":"C Moore","year":"2021","unstructured":"Moore C, Hsu CC, Chen WM, et al. Personalized ultrafractionated stereotactic adaptive radiotherapy (PULSAR) in preclinical models enhances Single-Agent immune checkpoint Blockade. Int J Radiat Oncol Biol Phys Aug. 2021;1(5):1306\u201316. https:\/\/doi.org\/10.1016\/j.ijrobp.2021.03.047.","journal-title":"Int J Radiat Oncol Biol Phys Aug"},{"issue":"9","key":"2691_CR14","doi-asserted-by":"publisher","first-page":"1276","DOI":"10.1001\/jamaoncol.2019.1478","volume":"1","author":"W Theelen","year":"2019","unstructured":"Theelen W, Peulen HMU, Lalezari F, et al. Effect of pembrolizumab after stereotactic body radiotherapy vs pembrolizumab alone on tumor response in patients with advanced Non-Small cell lung cancer: results of the PEMBRO-RT phase 2 randomized clinical trial. JAMA Oncol Sep. 2019;1(9):1276\u201382. https:\/\/doi.org\/10.1001\/jamaoncol.2019.1478.","journal-title":"JAMA Oncol Sep"},{"issue":"10","key":"2691_CR15","doi-asserted-by":"publisher","first-page":"925","DOI":"10.1056\/NEJMoa1112824","volume":"8","author":"MA Postow","year":"2012","unstructured":"Postow MA, Callahan MK, Barker CA, et al. Immunologic correlates of the abscopal effect in a patient with melanoma. N Engl J Med Mar. 2012;8(10):925\u201331. https:\/\/doi.org\/10.1056\/NEJMoa1112824.","journal-title":"N Engl J Med Mar"},{"issue":"2","key":"2691_CR16","doi-asserted-by":"publisher","first-page":"e2238","DOI":"10.7759\/cureus.2238","volume":"27","author":"JM Tsui","year":"2018","unstructured":"Tsui JM, Mihalcioiu C, Cury FL. Abscopal effect in a stage IV melanoma patient who progressed on pembrolizumab. Cureus Feb. 2018;27(2):e2238. https:\/\/doi.org\/10.7759\/cureus.2238.","journal-title":"Cureus Feb"},{"key":"2691_CR17","doi-asserted-by":"crossref","unstructured":"Drake C. Radiation-Induced Immune Modulation. In: DeWeese TaL, M, ed. Molecular Determinants of Radiation Response. Springer; 2011:251\u2013263. Current Cancer Research.","DOI":"10.1007\/978-1-4419-8044-1_12"},{"key":"2691_CR18","unstructured":"Keytruda [package insert]. Merck Sharp & Dohme LLC; 2024."}],"container-title":["Radiation Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13014-025-02691-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13014-025-02691-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13014-025-02691-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,21]],"date-time":"2025-08-21T05:27:41Z","timestamp":1755754061000},"score":1,"resource":{"primary":{"URL":"https:\/\/ro-journal.biomedcentral.com\/articles\/10.1186\/s13014-025-02691-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,21]]},"references-count":18,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["2691"],"URL":"https:\/\/doi.org\/10.1186\/s13014-025-02691-y","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-5334919\/v1","asserted-by":"object"}]},"ISSN":["1748-717X"],"issn-type":[{"value":"1748-717X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,8,21]]},"assertion":[{"value":"26 October 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 July 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 August 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Written informed consent for publication of their clinical details and\/or clinical images was obtained from the legal guardian of the patient. A copy of the consent form is available for review by the Editor of this journal.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"132"}}